已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Smaller Differences in the Comparative Effectiveness of Biologics in Reducing Asthma-Related Hospitalizations Compared With Overall Exacerbations

哮喘 医学 哮喘恶化 梅德林 重症监护医学 急诊医学 内科学 政治学 法学
作者
Ayobami Akenroye,James Marshall,Andrew Simon,Christian Hague,Rebecca Costa,Aziza Jamal‐Allial,Cheryl N. McMahill‐Walraven,Katie Haffenreffer,Amy Han,Ann Chen Wu
出处
期刊:The Journal of Allergy and Clinical Immunology: In Practice [Elsevier BV]
卷期号:12 (6): 1568-1574.e2 被引量:2
标识
DOI:10.1016/j.jaip.2024.02.034
摘要

ABSTRACT

Background

Evidence on the comparative effectiveness of respiratory biologics remains sparse.

Objective

We sought to evaluate the comparative effectiveness of omalizumab, mepolizumab, benralizumab, and dupilumab in a matched retrospective cohort of patients with asthma.

Methods

We identified patients with asthma aged ≥18 years who were incident users of these biologics between November 1, 2018, and June 30, 2023, in administrative claims data from the FDA's Sentinel System and Merative™ MarketScan® Commercial Database. We compared asthma-related exacerbations and hospitalizations in the 12-months since biologic prescription in pairwise comparisons of propensity score-matched cohorts. Covariates used in matching included age, sex, allergic comorbidities, baseline asthma medications use, and the Charlson Comorbidity Index. Incidence rate ratios (IRR) and 95% CIs were estimated using negative binomial regression models.

Results

Eight hundred and ninety-three mepolizumab users, 1300 benralizumab, 1170 omalizumab, and 1863 dupilumab patients were identified. The average age was 55 years and two-thirds of the participants were female. At baseline, over 80% of these individuals had an active prescription for an inhaled corticosteroid. Almost half of patients on dupilumab had concomitant nasal polyposis compared to 6-13% of patients on the other biologics. Covariates were balanced after matching. In matched analyses, dupilumab was associated with the lowest incidence of exacerbations over the follow-up period (vs dupilumab): mepolizumab (IRR: 1.36; 95% CI: 1.12-1.64), omalizumab (IRR: 1.33; 95% CI: 1.13-1.58), benralizumab (IRR: 1.19; 95% CI: 1.00-1.41). For exacerbations leading to hospitalizations, benralizumab and mepolizumab were associated with the lowest incidence of hospitalizations and the greatest difference was between mepolizumab vs dupilumab (IRR 0.76; 0.56 - 1.03).

Conclusion

Dupilumab was associated with the lowest incidence of overall exacerbations and mepolizumab with the lowest incidence of asthma hospitalizations in this administrative claims-based cohort of individuals with asthma. Despite matching propensity scores, residual confounding, such as baseline eosinophil count, may explain some of these findings.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI2S的应助被勤奋笑卉采纳,获得10
1秒前
Lov完成签到 ,获得积分10
2秒前
EmeraldFlamel完成签到 ,获得积分10
2秒前
3秒前
3秒前
不做科研发布了新的文献求助10
3秒前
Xtay完成签到 ,获得积分10
5秒前
6秒前
7秒前
alwry完成签到,获得积分10
7秒前
quan完成签到,获得积分10
7秒前
车车发布了新的文献求助10
8秒前
科研通AI6.4的应助被咎如天采纳,获得10
10秒前
琳琅完成签到,获得积分10
11秒前
11秒前
王泉林发布了新的文献求助10
12秒前
可爱的函函的应助被李锦奥采纳,获得10
13秒前
13秒前
磊少完成签到,获得积分10
13秒前
snowman完成签到 ,获得积分10
14秒前
cdy完成签到 ,获得积分10
14秒前
CucRuotThua发布了新的文献求助10
14秒前
玥越完成签到,获得积分10
15秒前
lnx的应助被阿切尔代采纳,获得60
16秒前
琳琅发布了新的文献求助10
16秒前
汉堡包的应助被酷炫的咪崽采纳,获得10
17秒前
17秒前
泥火山发布了新的文献求助10
17秒前
18秒前
18秒前
王泉林完成签到,获得积分10
19秒前
慕青的应助被011采纳,获得10
21秒前
vvr完成签到 ,获得积分10
21秒前
852的应助被Cyx采纳,获得30
23秒前
aiyiying完成签到,获得积分10
23秒前
25秒前
小山大王完成签到 ,获得积分10
25秒前
小米布朗尼完成签到 ,获得积分10
25秒前
25秒前
27秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8165576
求助须知:如何正确求助?哪些是违规求助? 9559107
关于积分的说明 21748964
捐赠科研通 7756283
什么是DOI,文献DOI怎么找? 3428926
关于科研通互助平台的介绍 2553233
邀请新用户注册赠送积分活动 2473520